Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours

Published:2024-08 Issue:8 Volume:63 Page:1191-1204
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Fernandez-Teruel Carlos^ORCID,Cullberg Marie^ORCID,Eberlein Cath^ORCID,Barry Simon T.^ORCID,Zhou Diansong^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01407-x.pdf

Reference22 articles.

1. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem. 2010;10(4):458–77. https://doi.org/10.2174/156802610790980602.

2. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11(4):873–87. https://doi.org/10.1158/1535-7163.MCT-11-0824-T.

3. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–70. https://doi.org/10.1056/NEJMoa2214131.

4. US Food and Drug Administration: FDA approves capivasertib with fulvestrant for breast cancer. 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer. Accessed 27 Feb 2024.

5. Neven P, Hamilton E, Pistilli B, Borges V, Campone M, Foukakis T, et al. 206P—Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): phase 1b data from CAPItello-292. In: Poster presented at ESMO Breast Cancer; 11–13 May 2023; Berlin.